Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05900180 · ClinicalTrials.gov registry record · NA
Pediatric Speech Therapy Session Frequency and Speech Outcomes
A NA study of Pediatric and Language Disorders in Children, sponsored by Connecticut Children's Medical Center.
- Active
- Registry status
- NA
- Development phase
- 39
- Enrollment target
- 1
- Study location
NCT05900180: Active NA study of Pediatric and Language Disorders in Children, sponsored by Connecticut Children's Medical Center.
NCT05900180 is a NA study of Pediatric and Language Disorders in Children that is active but no longer recruiting, run by Connecticut Children's Medical Center. The registered enrollment target is 39 participants, below the 73-participant average among 8 other Pediatric trials with a reported enrollment target (47% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05900180, a NA study of Pediatric and Language Disorders in Children, is active but no longer recruiting, sponsored by Connecticut Children's Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 39 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to compare speech therapy outcomes in children ages 18 months to 16 years who participate in weekly speech therapy with home programming versus every-other week speech therapy with home programming in outpatient speech therapy. The main question it aims to answer is: Does a change in how often speech therapy sessions are delivered show an increased benefit in language and articulation standardized test scores? Participants will be randomly assigned to either (1) weekly or (2) every-other-week speech therapy for a total of 8 sessions. Researchers will compare these two groups to see if there are differences in speech outcomes.
Primary Outcome
Scores on the following standardized measures: Goldman Fristoe Test of Articulation- Third Edition (GFTA-3) ; Average Standard Score range is from 86-114; an increase in standard score indicates improvement in intelligibility.
Conditions Studied
Interventions
- BEHAVIORAL Speech Therapy
Study Locations (1)
Connecticut
- Connecticut Children's Medical Center - Hartford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2023-01-01 |
| Est. Completion | 2027-12-30 |
| Phase | NA |
What the registry record for NCT05900180 still lists
NCT05900180 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 39 participants, a relatively small participant target, below the 73-participant average among 8 other Pediatric trials with a reported enrollment target (47% lower).
The record links to 7 conditions, with Pediatric appearing as the primary indexed condition, and to 1 intervention - of which Speech Therapy is the first listed.
NCT05900180 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT05900180 about?
NCT05900180 is a clinical study titled "Pediatric Speech Therapy Session Frequency and Speech Outcomes". The goal of this clinical trial is to compare speech therapy outcomes in children ages 18 months to 16 years who participate in weekly speech therapy with home programming versus every-other week speech therapy with home programming in outpatient speech therapy. The main question it aims to answer i...
What is the current status of trial NCT05900180?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 39 participants. The study started on 2023-01-01. Estimated completion is 2027-12-30.
What conditions does trial NCT05900180 study?
This clinical trial studies the following conditions: Pediatric, Language Disorders in Children, Communication Disorder, Childhood, Speech Therapy, Articulation Disorders in Children.
What interventions are being tested in trial NCT05900180?
The interventions under investigation include: Speech Therapy (BEHAVIORAL).
Who is sponsoring clinical trial NCT05900180?
This trial is sponsored by Connecticut Children's Medical Center, which has 55 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05900180 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pediatric
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05900180's enrollment target sits among peer trials
39 6th of 8 higher than 3 of 8 other Pediatric trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pediatric trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Comparing Two Models of Well-Child Care for Black Families
RECRUITING · NA
-
Quantifying Motor Network Dynamics to Predict and Enhance Outcomes in Pediatric Dystonia
RECRUITING · NA
-
Investigation Of Bioabsorbable Screws In Pediatric Orthopedic Surgery
RECRUITING · NA
-
Pediatric Adhesion and New Dermal Approach Study
ACTIVE NOT RECRUITING · NA
-
Hypertonic Saline for Mild TBI in Pediatric Patients
ACTIVE NOT RECRUITING · NA
-
A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465592 · 39 participants · Phase 1
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
- NCT03961776 · 39 participants
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
- NCT04050280 · 39 participants · Phase 2
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- NCT04190862 · 39 participants · Phase 1
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI